Comparative Pharmacology
Head-to-head clinical analysis: LIORESAL versus METHOCARBAMOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIORESAL versus METHOCARBAMOL.
LIORESAL vs METHOCARBAMOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
None Documented
None Documented
Clinical Note
moderateMethocarbamol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone propionate."
Clinical Note
moderateMethocarbamol + Venlafaxine
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine."
Clinical Note
moderateMethocarbamol + Nefazodone
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone."
Clinical Note
moderateTerminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant.
Category C
Category A/B
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
Methocarbamol + Stiripentol
"The risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol."